Descripción del proyecto
Nuevo enfoque de tratamiento para el trastorno depresivo mayor
El trastorno depresivo mayor (TDM) es un problema de salud pública cada vez más acuciante en Europa que genera una carga económica importante. Las recaídas en el TDM son habituales, ya que las respuestas de los individuos a los tratamientos varían considerablemente. La falta de conocimiento de las causas de la variabilidad en los resultados de los tratamientos impide mejorar un régimen de tratamiento adecuado. Por lo general, se acepta que el TDM es un trastorno heterogéneo. El proyecto SUBTREAT, financiado por el Consejo Europeo de Investigación, considera que el subtipo es la clave para relacionar la causa y la heterogeneidad del efecto del tratamiento. Desglosará los resultados heterogéneos del tratamiento del TDM en subtipos definidos con más precisión y con causas distintas. El equipo de SUBTREAT utilizará enfoques de ciencia de datos punteros para identificar nuevos subtipos, determinar las causas de divergencia y desarrollar un nuevo algoritmo de predicción de los resultados del tratamiento.
Objetivo
Major depressive disorder (MDD) is a leading contributor to disability and suicide. It is the most costly brain disorder in Europe. Although multiple treatments are of proven efficacy, individual responses to treatments vary considerably and MDD recurrence is common. There is considerable motivation to improve treatment regimen for individuals with MDD. However, it has been challenging because of the fundamental lack of understanding about the causes of variable treatment outcomes. MDD is widely accepted as a heterogeneous disorder; yet, most research strategies effectively consider MDD as a single disorder. Progress in understanding the variable treatment response will depend on “patient stratification”, i.e. identifying and accounting for patient heterogeneity when evaluating treatment efficacy.
SUBTREAT proposes a unique direction which considers subtype as the key to link aetiological and treatment effect heterogeneity. Our approach is to break down the heterogeneous treatment outcomes of MDD into more narrowly defined subtypes with divergent aetiologies. Specially, I propose three work packages: 1) dissect treatment heterogeneity across subtypes; a particularly innovative aspect of SUBTREAT is that we will use advanced data science approaches to identify novel subtypes which correlate with differential treatment outcomes; 2) determine divergent causes underlying MDD subtypes; we will comprehensively investigate causes at three levels including genetic and causal epidemiological risk factors, and brain cell types; 3) develop a novel prediction algorithm for treatment outcomes stratified by patient subgroups. SUBTREAT will illuminate the causes of MDD subtypes and the principal patterns of how subtypes contribute to differential long-term treatment outcomes. SUBTREAT findings will promote targeted drug development and treatment optimization for patient subgroups to achieve precision psychiatry.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régimen de financiación
HORIZON-ERC - HORIZON ERC GrantsInstitución de acogida
17177 Stockholm
Suecia